ST2, PIVKA-II, CEA, CA125 and their combinations in elderly liver metastases cancers: Development of a diagnostic scoring model
World Journal of Gastrointestinal Oncology · 01.04.2026
DOI: 10.4251/wjgo.118940 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Gastrointestinal Oncology, online erschienen am 01.04.2026. Verfasst von Yun Cheng und 2 weiteren Autor:innen.
Abstract (Originalsprache)
BACKGROUND Liver metastasis worsens prognosis in elderly colorectal and lung cancer patients, yet early diagnosis is hindered by atypical symptoms and suboptimal biomarker sensitivity. Soluble growth-stimulating gene 2 (ST2), protein induced by vitamin K absence or antagonist-II (PIVKA-II), carcinoembryonic antigen (CEA), and carbohydrate antigen 125 (CA125) have each been implicated in tumor progression and hepatic microenvironment remodeling, but their synergistic diagnostic value in this population remains unevaluated. We hypothesize that integrating these four serum markers with clinical risk factors into a weighted scoring model will improve diagnostic accuracy and enable reliable risk stratification in elderly patients. AIM To identify optimal biomarkers and develop a diagnostic scoring model for elderly liver metastatic cancers. METHODS This retrospective study enrolled 480 elderly patients with colorectal or lung cancer. Patients were randomly divided 7:3 into construction (n = 336) and validation (n = 144) sets. Univariate analysis and binary logistic regression identified independent risk factors for liver metastases. A scoring model incorporating ST2, PIVKA-II, CEA, CA125, and fatty liver history was developed. Model performance was assessed using receiver operating characteristic curves, area under the curve, calibration curves, and C-index. RESULTS Serum ST2, PIVKA-II, CEA, and CA125 levels and fatty liver history were significantly higher in the liver metastasis group (P < 0.05). All five were confirmed as independent risk factors for liver metastasis (P < 0.05). The ST2 + PIVKA-II + CEA + CA125 combination achieved the optimal balance between sensitivity and specificity. A scoring model was developed: Fatty liver history (2 points), ST2 ≥ 64.34 pg/mL (2), PIVKA-II ≥ 40 mAU/mL (3), CEA ≥ 5.7 ng/mL (3), CA125 ≥ 35 U/mL (2). Liver metastasis incidence increased with risk level: Low (0-5 points), intermediate (6-9), and high (10-12). The C-index was 0.840 in the construction group and 0.786 in the validation group, with calibration curves closely matching ideal curves. CONCLUSION The combined four-marker panel and novel scoring model effectively predict liver metastasis risk, offering a reliable tool for early diagnosis and risk stratification in elderly patients.
Zitieren
APA
Cheng, Y., Sun, Y., & He, Y. (2026). ST2, PIVKA-II, CEA, CA125 and their combinations in elderly liver metastases cancers: Development of a diagnostic scoring model. World Journal of Gastrointestinal Oncology. https://doi.org/10.4251/wjgo.118940
Vancouver
Cheng Y, Sun Y, He Y. ST2, PIVKA-II, CEA, CA125 and their combinations in elderly liver metastases cancers: Development of a diagnostic scoring model. World Journal of Gastrointestinal Oncology. 2026. doi:10.4251/wjgo.118940
BibTeX
@article{Cheng2026,
author = {Cheng, Yun and Sun, Yan-Sha and He, Yong-Ming},
title = {ST2, PIVKA-II, CEA, CA125 and their combinations in elderly liver metastases cancers: Development of a diagnostic scoring model},
journal = {World Journal of Gastrointestinal Oncology},
year = {2026},
doi = {10.4251/wjgo.118940}
}
EUVIMED